Ufff! Tiempos interesantes!!!

Solo Eye Drop Treatment in Development for Keratoconus

Avedro comienza a cotizar en bolsa!! Lo cuál nos hace suponer que la empresa seguirá creciendo y desarrollando nuevos avances en el campo del CXL.

At Avedro, we are a leader in the field of corneal remodeling developing treatments for patients like Daniel. So thankful that Daniel could join us to celebrate this company milestone and ring the closing bell with our CEO, Reza #RewriteTomorrow #AvedroIPO pic.twitter.com/4ylOddBXc0

— Avedro (@Avedro_Inc) February 15, 2019